Cite
MLA Citation
R. Bissonnette et al.. “Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).” Journal of the European Academy of Dermatology and Venereology, vol. 32, 2018, pp. 1507–1514. http://access.bl.uk/ark:/81055/vdc_100068502565.0x00002b